Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.» Read More
At least three companies are on the cutting edge of new treatments for perhaps the most feared disease known to mankind.
China has found two more cases of a new strain of bird flu and one of the victims has died, bringing to nine the number of confirmed human infections from the previously unknown flu type.
India's top court has dealt a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales.
Share price may already seem high but Jim Cramer thinks it deserves to be even higher.
Facebook appointed a former Genentech executive to its board of directors, the social networking company's latest move to expand its boardroom following its initial public offering last May.
Swiss citizens voted on Sunday to impose some of the world's strictest controls on executive pay, forcing public companies to give shareholders a binding vote on compensation, result projections showed.
European shares suffered their biggest daily drop this month after gloomy earnings and weak U.S. economic data hit sentiment on Wednesday and left some positioning for further falls in the near-term.
U.S. stock index futures pointed to a slightly higher open on Wednesday, with eyes on the Federal Reserve’s first policy statement of 2013.
Severin Schwan, CEO of Roche, tells CNBC that 2012 was a very good year for Roche with the company outgrowing their markets in both Pharma and Diagnostics by five and four percent.
TheStreet.com offers up 13 biotech predictions for 2013.
As Christmas overeating gives way to under-fulfilled new year diets, the pharmaceutical industry's appetite has been whetted for a fresh surge in business.
Some of the names on the move ahead of the open.
Severin Schwan, CEO of Roche, tells CNBC, that the company is on track to achieve its full year target, but they are sticking to the guidance that they gave at the beginning of the year.
Andrew Weiss, head of Life Science at Vontobel, tells CNBC, Roche is the best pick in the European sector, the company with the least amount of problems and innovation within the company.
CNBC's Kayla Tausche reports on Illumina playing offense against Roche's hostile takeover bid, and the FMHR crew share their final trades of the hour.
CNBC's David Faber reports the latest details on Illumina's recommendation to shareholders to reject Roche's takeover offer.
A serious warning is out to patients, doctors and hospitals telling everyone to beware of a fake version of Roche's cancer-fighting drug Avastin. Insight with Scott Gottlieb, MD.
Considering Illumina just adopted a poison pill defense strategy, you might think a deal with Roche is out of the question. But Karen Finerman says it's not.
Karen Finerman, Metropolitan Capital Advisors, and Fast Money trader, provides insight on what's next for Illumina, on the heels its recent rejection of Roche's offer.
Insight on the value that will be created by a transaction with Illumina, with Severin Schwan, Roche CEO, who discusses Roche's offer for Illumina.